DLL3 and neuroendocrine carcinoma: Moreover, as DLL3 expression is restricted to the brain but aberrantly expressed in many neuroendocrine cancers, DLL3 was an early immunotherapeutic target in small cell lung cancer (SCLC)3 and neuroendocrine prostate cancer4.